DC-6001 is under clinical development by DynamiCure Biotechnology and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DC-6001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DC-6001 is under development for the treatment of metastatic solid tumors such as metastatic breast cancer, head and neck cancer, colorectal cancer, gastric cancer, non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, ovarian cancer, cervical cancer, glioblastoma multiforme (GBM). The therapeutic candidate acts by targeting CD93. It is administered through intravenous route.
DynamiCure Biotechnology overview
DynamiCure Biotechnology (DynamiCure) is a biotechnology company focusing on treatment of cancer, autoimmune, and other diseases. DynamiCure is headquartered in Waltham, Massachusetts, the US.
For a complete picture of DC-6001’s drug-specific PTSR and LoA scores, buy the report here.